PARP1 and Familial prostate cancer: According to other results that were published not too long ago, the loss of the chromatin remodeler chromodomain-helicase-DNA-binding protein 1 (CHD1), which is often seen in advanced prostate cancer, is associated with an increase in the responsiveness to PARP inhibitors.